Expertise in
5
conditions

Dr. Paul M. Harari

Radiation Oncology
University Of Wisconsin Medical Foundation Inc
600 Highland Ave, 
Madison, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
5
conditions
University Of Wisconsin Medical Foundation Inc
600 Highland Ave, 
Madison, WI 

Overview

Paul Harari is a Radiation Oncologist in Madison, Wisconsin. Dr. Harari is highly rated in 5 conditions, according to our data. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Human Papillomavirus Infection, Adenoid Cystic Carcinoma, Laryngeal Cancer, and Gastrostomy. Dr. Harari is currently accepting new patients.

His clinical research consists of co-authoring 153 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Radiation Oncology

Licenses

Radiology in WI

Hospital Affiliations

University Of Wi Hospitals & Clinics Authority

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Quartz
  • HMO
  • POS
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS

Locations

UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION INC
600 Highland Ave, Madison, WI 53792

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: January 14, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Lapatinib
Study Phase: Phase 2
Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment
Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment
Enrollment Status: Terminated
Publish Date: March 08, 2023
Intervention Type: Other, Drug
Study Phase: Phase 2
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
Enrollment Status: Terminated
Publish Date: November 21, 2019
Intervention Type: Device
View 9 Less Clinical Trials

153 Total Publications

Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience.
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience.
Journal: Journal of the National Cancer Institute
Published: August 07, 2025
Similar Doctors
Expertise in
14
conditions
Dr. Andrew M. Baschnagel
Radiation Oncology
Expertise in
14
conditions
Dr. Andrew M. Baschnagel
Radiation Oncology

University Of Wisconsin Medical Foundation Inc

600 Highland Ave, 
Madison, WI 
 (0.1 miles away)
608-263-6400
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Baschnagel is a Radiation Oncologist in Madison, Wisconsin. Dr. Baschnagel has been practicing medicine for over 17 years is highly rated in 14 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Gamma Knife Radiosurgery. Dr. Baschnagel is currently accepting new patients.

Expertise in
31
conditions
Dr. Steven Howard
Radiation Oncology
Expertise in
31
conditions
Dr. Steven Howard
Radiation Oncology

University Of Wisconsin Medical Foundation Inc

600 Highland Ave, 
Madison, WI 
 (0.1 miles away)
608-263-6400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Howard is a Radiation Oncologist in Madison, Wisconsin. Dr. Howard is highly rated in 31 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Glioma, and Rhizotomy.

Expertise in
20
conditions
Dr. Zachary S. Morris
Radiation Oncology
Expertise in
20
conditions
Dr. Zachary S. Morris
Radiation Oncology

University Of Wisconsin Medical Foundation Inc

600 Highland Ave, 
Madison, WI 
 (0.1 miles away)
608-263-6400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Zachary Morris is a Radiation Oncologist in Madison, Wisconsin. Dr. Morris is highly rated in 20 conditions, according to our data. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma Embryonal, and Epithelioid Sarcoma. Dr. Morris is currently accepting new patients.

Frequently Asked Questions about Dr. Paul M. Harari

How do I make an appointment with Dr. Paul M. Harari?

You can book an appointment with Dr. Paul M. Harari by calling their office at 608-263-6400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul M. Harari a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul M. Harari is classified as an Elite expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul M. Harari specialize in?

While Dr. Paul M. Harari is a Radiation Oncology, they have specific expertise in Head and Neck Squamous Cell Carcinoma (HNSCC), Human Papillomavirus Infection, and Adenoid Cystic Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Paul M. Harari participate in research or clinical trials?

Yes. Dr. Paul M. Harari has published 153 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Dr. Paul M. Harari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul M. Harari accept my insurance?

Dr. Paul M. Harari accepts most major insurance plans, including Anthem BCBS and Aspirus Arise Health. We recommend calling the office directly at 608-263-6400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Harari's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile